Novel Drug Safe, Effective in Relapsing MS: 2-Year Data

The investigational evobrutinib, an Bruton's tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Medscape Medical News